Jacobs Levy Equity Management
IDXG

Jacobs Levy Equity Management’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Jacobs Levy Equity Management’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-129
Closed -$59K – 974
2014
Q1 		$59K Sell
129
-109
-46% -$56.6K ﹤0.01% 868
2013
Q4 		$114K Sell
238
-148
-38% -$72.3K ﹤0.01% 903
2013
Q3 		$186K Buy
386
+46
+14% +$22K ﹤0.01% 864
2013
Q2 		$160K Buy
+340
New +$154K ﹤0.01% 916

Other funds holding IDXG

HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $126M AUM 15.32% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Jacobs Levy Equity Management's IDXG Position: Q2 2014 in Review

Jacobs Levy Equity Management sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q2 2014, closing a stake of 129 shares — an estimated $59K sold.

Jacobs Levy Equity Management first reported a position in IDXG in Q2 2013 and held it in 4 quarters. The position peaked at $186K in Q3 2013. 28 funds tracked by Wall St. Rank hold IDXG as of Q2 2014.

  • Jacobs Levy Equity Management reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 129 Interpace Biosciences, Inc. Common Stock shares in Q2 2014, an estimated $59K.
  • Jacobs Levy Equity Management first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 4 quarters.
  • Jacobs Levy Equity Management's Interpace Biosciences, Inc. Common Stock position peaked at $186K in Q3 2013.
  • 28 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q2 2014.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2014, filed 14 Aug 2014.